nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—ABCB1—kidney cancer	0.173	1	CbGaD
Paroxetine—ABCB1—Temsirolimus—kidney cancer	0.0399	0.0874	CbGbCtD
Paroxetine—CYP2D6—Temsirolimus—kidney cancer	0.0376	0.0823	CbGbCtD
Paroxetine—CYP2C8—Pazopanib—kidney cancer	0.031	0.0678	CbGbCtD
Paroxetine—CYP2B6—Sorafenib—kidney cancer	0.0237	0.0519	CbGbCtD
Paroxetine—CYP2C9—Capecitabine—kidney cancer	0.0225	0.0493	CbGbCtD
Paroxetine—CYP2C8—Erlotinib—kidney cancer	0.0221	0.0484	CbGbCtD
Paroxetine—ABCB1—Pazopanib—kidney cancer	0.021	0.0459	CbGbCtD
Paroxetine—CYP2C8—Paclitaxel—kidney cancer	0.0202	0.0443	CbGbCtD
Paroxetine—CYP2D6—Pazopanib—kidney cancer	0.0197	0.0432	CbGbCtD
Paroxetine—ABCB1—Dactinomycin—kidney cancer	0.0192	0.042	CbGbCtD
Paroxetine—CYP2C8—Sorafenib—kidney cancer	0.018	0.0393	CbGbCtD
Paroxetine—ABCB1—Gemcitabine—kidney cancer	0.0151	0.0332	CbGbCtD
Paroxetine—ABCB1—Erlotinib—kidney cancer	0.0149	0.0327	CbGbCtD
Paroxetine—CYP2B6—Doxorubicin—kidney cancer	0.0144	0.0315	CbGbCtD
Paroxetine—CYP2C9—Paclitaxel—kidney cancer	0.0141	0.0309	CbGbCtD
Paroxetine—CYP2D6—Erlotinib—kidney cancer	0.0141	0.0309	CbGbCtD
Paroxetine—ABCB1—Paclitaxel—kidney cancer	0.0137	0.03	CbGbCtD
Paroxetine—CYP2C9—Sorafenib—kidney cancer	0.0125	0.0274	CbGbCtD
Paroxetine—ABCB1—Sorafenib—kidney cancer	0.0122	0.0266	CbGbCtD
Paroxetine—ABCB1—Vinblastine—kidney cancer	0.012	0.0263	CbGbCtD
Paroxetine—ABCB1—Vincristine—kidney cancer	0.0118	0.0258	CbGbCtD
Paroxetine—CYP2D6—Sorafenib—kidney cancer	0.0115	0.0251	CbGbCtD
Paroxetine—CYP2D6—Vinblastine—kidney cancer	0.0113	0.0248	CbGbCtD
Paroxetine—ABCB1—Sunitinib—kidney cancer	0.00985	0.0216	CbGbCtD
Paroxetine—CHRM3—ureter—kidney cancer	0.00842	0.364	CbGeAlD
Paroxetine—ABCB1—Doxorubicin—kidney cancer	0.00738	0.0162	CbGbCtD
Paroxetine—CYP2D6—Doxorubicin—kidney cancer	0.00695	0.0152	CbGbCtD
Paroxetine—CYP2C9—urine—kidney cancer	0.00197	0.0851	CbGeAlD
Paroxetine—TACR1—renal system—kidney cancer	0.00163	0.0703	CbGeAlD
Paroxetine—HTR2A—urine—kidney cancer	0.00162	0.0701	CbGeAlD
Paroxetine—CYP2D6—urine—kidney cancer	0.00148	0.0639	CbGeAlD
Paroxetine—CHRM3—renal system—kidney cancer	0.000669	0.0289	CbGeAlD
Paroxetine—CHRM3—kidney—kidney cancer	0.000647	0.0279	CbGeAlD
Paroxetine—SLC6A2—gonad—kidney cancer	0.000593	0.0256	CbGeAlD
Paroxetine—CYP2C8—renal system—kidney cancer	0.000543	0.0234	CbGeAlD
Paroxetine—CYP2B6—nephron tubule—kidney cancer	0.000536	0.0231	CbGeAlD
Paroxetine—CYP2C8—kidney—kidney cancer	0.000525	0.0227	CbGeAlD
Paroxetine—CYP2B6—renal system—kidney cancer	0.000487	0.021	CbGeAlD
Paroxetine—CYP2B6—kidney—kidney cancer	0.000471	0.0203	CbGeAlD
Paroxetine—CYP2B6—gonad—kidney cancer	0.000437	0.0189	CbGeAlD
Paroxetine—HTR2A—renal system—kidney cancer	0.000397	0.0172	CbGeAlD
Paroxetine—HTR2A—kidney—kidney cancer	0.000384	0.0166	CbGeAlD
Paroxetine—CYP2D6—renal system—kidney cancer	0.000362	0.0156	CbGeAlD
Paroxetine—HTR2A—gonad—kidney cancer	0.000356	0.0154	CbGeAlD
Paroxetine—CYP2D6—kidney—kidney cancer	0.00035	0.0151	CbGeAlD
Paroxetine—ABCB1—nephron tubule—kidney cancer	0.000286	0.0124	CbGeAlD
Paroxetine—ABCB1—renal system—kidney cancer	0.00026	0.0112	CbGeAlD
Paroxetine—ABCB1—kidney—kidney cancer	0.000252	0.0109	CbGeAlD
Paroxetine—ABCB1—cortex of kidney—kidney cancer	0.000245	0.0106	CbGeAlD
Paroxetine—ABCB1—gonad—kidney cancer	0.000233	0.0101	CbGeAlD
Paroxetine—Flatulence—Capecitabine—kidney cancer	5.82e-05	0.000196	CcSEcCtD
Paroxetine—Dry skin—Doxorubicin—kidney cancer	5.79e-05	0.000195	CcSEcCtD
Paroxetine—Dysgeusia—Capecitabine—kidney cancer	5.78e-05	0.000194	CcSEcCtD
Paroxetine—Dizziness—Sunitinib—kidney cancer	5.78e-05	0.000194	CcSEcCtD
Paroxetine—Feeling abnormal—Gemcitabine—kidney cancer	5.78e-05	0.000194	CcSEcCtD
Paroxetine—Shock—Paclitaxel—kidney cancer	5.78e-05	0.000194	CcSEcCtD
Paroxetine—Vomiting—Sorafenib—kidney cancer	5.78e-05	0.000194	CcSEcCtD
Paroxetine—Orthostatic hypotension—Doxorubicin—kidney cancer	5.77e-05	0.000194	CcSEcCtD
Paroxetine—Nervous system disorder—Paclitaxel—kidney cancer	5.76e-05	0.000194	CcSEcCtD
Paroxetine—Hypokalaemia—Doxorubicin—kidney cancer	5.75e-05	0.000193	CcSEcCtD
Paroxetine—Thrombocytopenia—Paclitaxel—kidney cancer	5.75e-05	0.000193	CcSEcCtD
Paroxetine—Tachycardia—Paclitaxel—kidney cancer	5.73e-05	0.000193	CcSEcCtD
Paroxetine—Rash—Sorafenib—kidney cancer	5.73e-05	0.000193	CcSEcCtD
Paroxetine—Dermatitis—Sorafenib—kidney cancer	5.72e-05	0.000192	CcSEcCtD
Paroxetine—Back pain—Capecitabine—kidney cancer	5.71e-05	0.000192	CcSEcCtD
Paroxetine—Breast disorder—Doxorubicin—kidney cancer	5.71e-05	0.000192	CcSEcCtD
Paroxetine—Skin disorder—Paclitaxel—kidney cancer	5.7e-05	0.000192	CcSEcCtD
Paroxetine—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	5.69e-05	0.000191	CcSEcCtD
Paroxetine—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	5.69e-05	0.000191	CcSEcCtD
Paroxetine—Headache—Sorafenib—kidney cancer	5.69e-05	0.000191	CcSEcCtD
Paroxetine—Muscle spasms—Capecitabine—kidney cancer	5.68e-05	0.000191	CcSEcCtD
Paroxetine—Hyperhidrosis—Paclitaxel—kidney cancer	5.68e-05	0.000191	CcSEcCtD
Paroxetine—Diarrhoea—Dactinomycin—kidney cancer	5.66e-05	0.00019	CcSEcCtD
Paroxetine—Nasopharyngitis—Doxorubicin—kidney cancer	5.65e-05	0.00019	CcSEcCtD
Paroxetine—Gastritis—Doxorubicin—kidney cancer	5.59e-05	0.000188	CcSEcCtD
Paroxetine—Alanine aminotransferase increased—Doxorubicin—kidney cancer	5.57e-05	0.000187	CcSEcCtD
Paroxetine—Muscular weakness—Doxorubicin—kidney cancer	5.57e-05	0.000187	CcSEcCtD
Paroxetine—Vision blurred—Capecitabine—kidney cancer	5.56e-05	0.000187	CcSEcCtD
Paroxetine—Vomiting—Sunitinib—kidney cancer	5.56e-05	0.000187	CcSEcCtD
Paroxetine—Body temperature increased—Gemcitabine—kidney cancer	5.54e-05	0.000186	CcSEcCtD
Paroxetine—Tremor—Capecitabine—kidney cancer	5.53e-05	0.000186	CcSEcCtD
Paroxetine—Rash—Sunitinib—kidney cancer	5.51e-05	0.000185	CcSEcCtD
Paroxetine—Dermatitis—Sunitinib—kidney cancer	5.51e-05	0.000185	CcSEcCtD
Paroxetine—Hypotension—Paclitaxel—kidney cancer	5.49e-05	0.000184	CcSEcCtD
Paroxetine—Ill-defined disorder—Capecitabine—kidney cancer	5.48e-05	0.000184	CcSEcCtD
Paroxetine—Headache—Sunitinib—kidney cancer	5.48e-05	0.000184	CcSEcCtD
Paroxetine—Dysphagia—Doxorubicin—kidney cancer	5.46e-05	0.000184	CcSEcCtD
Paroxetine—Influenza—Doxorubicin—kidney cancer	5.46e-05	0.000184	CcSEcCtD
Paroxetine—Asthma—Doxorubicin—kidney cancer	5.46e-05	0.000184	CcSEcCtD
Paroxetine—Anaemia—Capecitabine—kidney cancer	5.46e-05	0.000183	CcSEcCtD
Paroxetine—Hypersensitivity—Vincristine—kidney cancer	5.45e-05	0.000183	CcSEcCtD
Paroxetine—Eosinophilia—Doxorubicin—kidney cancer	5.41e-05	0.000182	CcSEcCtD
Paroxetine—Nausea—Sorafenib—kidney cancer	5.4e-05	0.000181	CcSEcCtD
Paroxetine—Pancreatitis—Doxorubicin—kidney cancer	5.36e-05	0.00018	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	5.35e-05	0.00018	CcSEcCtD
Paroxetine—Malaise—Capecitabine—kidney cancer	5.32e-05	0.000179	CcSEcCtD
Paroxetine—Angina pectoris—Doxorubicin—kidney cancer	5.32e-05	0.000179	CcSEcCtD
Paroxetine—Insomnia—Paclitaxel—kidney cancer	5.31e-05	0.000179	CcSEcCtD
Paroxetine—Vertigo—Capecitabine—kidney cancer	5.3e-05	0.000178	CcSEcCtD
Paroxetine—Asthenia—Vincristine—kidney cancer	5.3e-05	0.000178	CcSEcCtD
Paroxetine—Syncope—Capecitabine—kidney cancer	5.29e-05	0.000178	CcSEcCtD
Paroxetine—Leukopenia—Capecitabine—kidney cancer	5.29e-05	0.000178	CcSEcCtD
Paroxetine—Paraesthesia—Paclitaxel—kidney cancer	5.27e-05	0.000177	CcSEcCtD
Paroxetine—Vomiting—Dactinomycin—kidney cancer	5.26e-05	0.000177	CcSEcCtD
Paroxetine—Bronchitis—Doxorubicin—kidney cancer	5.25e-05	0.000177	CcSEcCtD
Paroxetine—Dyspnoea—Paclitaxel—kidney cancer	5.23e-05	0.000176	CcSEcCtD
Paroxetine—Somnolence—Paclitaxel—kidney cancer	5.22e-05	0.000175	CcSEcCtD
Paroxetine—Palpitations—Capecitabine—kidney cancer	5.22e-05	0.000175	CcSEcCtD
Paroxetine—Rash—Dactinomycin—kidney cancer	5.22e-05	0.000175	CcSEcCtD
Paroxetine—Nausea—Sunitinib—kidney cancer	5.19e-05	0.000175	CcSEcCtD
Paroxetine—Loss of consciousness—Capecitabine—kidney cancer	5.19e-05	0.000174	CcSEcCtD
Paroxetine—Pancytopenia—Doxorubicin—kidney cancer	5.19e-05	0.000174	CcSEcCtD
Paroxetine—Dyspepsia—Paclitaxel—kidney cancer	5.17e-05	0.000174	CcSEcCtD
Paroxetine—Cough—Capecitabine—kidney cancer	5.15e-05	0.000173	CcSEcCtD
Paroxetine—Dysuria—Doxorubicin—kidney cancer	5.11e-05	0.000172	CcSEcCtD
Paroxetine—Decreased appetite—Paclitaxel—kidney cancer	5.1e-05	0.000172	CcSEcCtD
Paroxetine—Hypertension—Capecitabine—kidney cancer	5.1e-05	0.000171	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Paclitaxel—kidney cancer	5.07e-05	0.00017	CcSEcCtD
Paroxetine—Fatigue—Paclitaxel—kidney cancer	5.06e-05	0.00017	CcSEcCtD
Paroxetine—Diarrhoea—Vincristine—kidney cancer	5.06e-05	0.00017	CcSEcCtD
Paroxetine—Pollakiuria—Doxorubicin—kidney cancer	5.05e-05	0.00017	CcSEcCtD
Paroxetine—Asthenia—Gemcitabine—kidney cancer	5.03e-05	0.000169	CcSEcCtD
Paroxetine—Myalgia—Capecitabine—kidney cancer	5.03e-05	0.000169	CcSEcCtD
Paroxetine—Chest pain—Capecitabine—kidney cancer	5.03e-05	0.000169	CcSEcCtD
Paroxetine—Arthralgia—Capecitabine—kidney cancer	5.03e-05	0.000169	CcSEcCtD
Paroxetine—Pain—Paclitaxel—kidney cancer	5.02e-05	0.000169	CcSEcCtD
Paroxetine—Constipation—Paclitaxel—kidney cancer	5.02e-05	0.000169	CcSEcCtD
Paroxetine—Anxiety—Capecitabine—kidney cancer	5.01e-05	0.000168	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	4.99e-05	0.000168	CcSEcCtD
Paroxetine—Photosensitivity reaction—Doxorubicin—kidney cancer	4.99e-05	0.000168	CcSEcCtD
Paroxetine—Weight increased—Doxorubicin—kidney cancer	4.97e-05	0.000167	CcSEcCtD
Paroxetine—Discomfort—Capecitabine—kidney cancer	4.97e-05	0.000167	CcSEcCtD
Paroxetine—Pruritus—Gemcitabine—kidney cancer	4.96e-05	0.000167	CcSEcCtD
Paroxetine—Weight decreased—Doxorubicin—kidney cancer	4.94e-05	0.000166	CcSEcCtD
Paroxetine—Hyperglycaemia—Doxorubicin—kidney cancer	4.93e-05	0.000166	CcSEcCtD
Paroxetine—Dry mouth—Capecitabine—kidney cancer	4.92e-05	0.000165	CcSEcCtD
Paroxetine—Nausea—Dactinomycin—kidney cancer	4.91e-05	0.000165	CcSEcCtD
Paroxetine—Pneumonia—Doxorubicin—kidney cancer	4.9e-05	0.000165	CcSEcCtD
Paroxetine—Dizziness—Vincristine—kidney cancer	4.89e-05	0.000164	CcSEcCtD
Paroxetine—Drowsiness—Doxorubicin—kidney cancer	4.87e-05	0.000164	CcSEcCtD
Paroxetine—Confusional state—Capecitabine—kidney cancer	4.86e-05	0.000163	CcSEcCtD
Paroxetine—Feeling abnormal—Paclitaxel—kidney cancer	4.84e-05	0.000163	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	4.83e-05	0.000162	CcSEcCtD
Paroxetine—Oedema—Capecitabine—kidney cancer	4.82e-05	0.000162	CcSEcCtD
Paroxetine—Gastrointestinal pain—Paclitaxel—kidney cancer	4.8e-05	0.000161	CcSEcCtD
Paroxetine—Diarrhoea—Gemcitabine—kidney cancer	4.8e-05	0.000161	CcSEcCtD
Paroxetine—Infection—Capecitabine—kidney cancer	4.79e-05	0.000161	CcSEcCtD
Paroxetine—Neuropathy peripheral—Doxorubicin—kidney cancer	4.77e-05	0.00016	CcSEcCtD
Paroxetine—Stomatitis—Doxorubicin—kidney cancer	4.75e-05	0.00016	CcSEcCtD
Paroxetine—Jaundice—Doxorubicin—kidney cancer	4.75e-05	0.00016	CcSEcCtD
Paroxetine—Shock—Capecitabine—kidney cancer	4.74e-05	0.000159	CcSEcCtD
Paroxetine—Urinary tract infection—Doxorubicin—kidney cancer	4.73e-05	0.000159	CcSEcCtD
Paroxetine—Conjunctivitis—Doxorubicin—kidney cancer	4.73e-05	0.000159	CcSEcCtD
Paroxetine—Nervous system disorder—Capecitabine—kidney cancer	4.73e-05	0.000159	CcSEcCtD
Paroxetine—Thrombocytopenia—Capecitabine—kidney cancer	4.72e-05	0.000159	CcSEcCtD
Paroxetine—Tachycardia—Capecitabine—kidney cancer	4.7e-05	0.000158	CcSEcCtD
Paroxetine—Vomiting—Vincristine—kidney cancer	4.7e-05	0.000158	CcSEcCtD
Paroxetine—Skin disorder—Capecitabine—kidney cancer	4.68e-05	0.000157	CcSEcCtD
Paroxetine—Sweating—Doxorubicin—kidney cancer	4.67e-05	0.000157	CcSEcCtD
Paroxetine—Urticaria—Paclitaxel—kidney cancer	4.66e-05	0.000157	CcSEcCtD
Paroxetine—Rash—Vincristine—kidney cancer	4.66e-05	0.000157	CcSEcCtD
Paroxetine—Hyperhidrosis—Capecitabine—kidney cancer	4.66e-05	0.000157	CcSEcCtD
Paroxetine—Dermatitis—Vincristine—kidney cancer	4.66e-05	0.000157	CcSEcCtD
Paroxetine—Haematuria—Doxorubicin—kidney cancer	4.64e-05	0.000156	CcSEcCtD
Paroxetine—Abdominal pain—Paclitaxel—kidney cancer	4.64e-05	0.000156	CcSEcCtD
Paroxetine—Body temperature increased—Paclitaxel—kidney cancer	4.64e-05	0.000156	CcSEcCtD
Paroxetine—Headache—Vincristine—kidney cancer	4.63e-05	0.000156	CcSEcCtD
Paroxetine—Hepatobiliary disease—Doxorubicin—kidney cancer	4.61e-05	0.000155	CcSEcCtD
Paroxetine—Epistaxis—Doxorubicin—kidney cancer	4.59e-05	0.000154	CcSEcCtD
Paroxetine—Sinusitis—Doxorubicin—kidney cancer	4.57e-05	0.000154	CcSEcCtD
Paroxetine—Agranulocytosis—Doxorubicin—kidney cancer	4.54e-05	0.000153	CcSEcCtD
Paroxetine—Hypotension—Capecitabine—kidney cancer	4.5e-05	0.000151	CcSEcCtD
Paroxetine—Vomiting—Gemcitabine—kidney cancer	4.46e-05	0.00015	CcSEcCtD
Paroxetine—Bradycardia—Doxorubicin—kidney cancer	4.45e-05	0.00015	CcSEcCtD
Paroxetine—Rash—Gemcitabine—kidney cancer	4.42e-05	0.000149	CcSEcCtD
Paroxetine—Dermatitis—Gemcitabine—kidney cancer	4.42e-05	0.000149	CcSEcCtD
Paroxetine—Haemoglobin—Doxorubicin—kidney cancer	4.39e-05	0.000148	CcSEcCtD
Paroxetine—Headache—Gemcitabine—kidney cancer	4.39e-05	0.000148	CcSEcCtD
Paroxetine—Nausea—Vincristine—kidney cancer	4.39e-05	0.000148	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Capecitabine—kidney cancer	4.39e-05	0.000148	CcSEcCtD
Paroxetine—Rhinitis—Doxorubicin—kidney cancer	4.38e-05	0.000147	CcSEcCtD
Paroxetine—Haemorrhage—Doxorubicin—kidney cancer	4.37e-05	0.000147	CcSEcCtD
Paroxetine—Hepatitis—Doxorubicin—kidney cancer	4.37e-05	0.000147	CcSEcCtD
Paroxetine—Insomnia—Capecitabine—kidney cancer	4.36e-05	0.000146	CcSEcCtD
Paroxetine—Hypoaesthesia—Doxorubicin—kidney cancer	4.35e-05	0.000146	CcSEcCtD
Paroxetine—Pharyngitis—Doxorubicin—kidney cancer	4.34e-05	0.000146	CcSEcCtD
Paroxetine—Paraesthesia—Capecitabine—kidney cancer	4.33e-05	0.000145	CcSEcCtD
Paroxetine—Hypersensitivity—Paclitaxel—kidney cancer	4.33e-05	0.000145	CcSEcCtD
Paroxetine—Oedema peripheral—Doxorubicin—kidney cancer	4.31e-05	0.000145	CcSEcCtD
Paroxetine—Connective tissue disorder—Doxorubicin—kidney cancer	4.3e-05	0.000144	CcSEcCtD
Paroxetine—Dyspnoea—Capecitabine—kidney cancer	4.3e-05	0.000144	CcSEcCtD
Paroxetine—Dyspepsia—Capecitabine—kidney cancer	4.24e-05	0.000143	CcSEcCtD
Paroxetine—Visual impairment—Doxorubicin—kidney cancer	4.21e-05	0.000142	CcSEcCtD
Paroxetine—Asthenia—Paclitaxel—kidney cancer	4.21e-05	0.000142	CcSEcCtD
Paroxetine—Decreased appetite—Capecitabine—kidney cancer	4.19e-05	0.000141	CcSEcCtD
Paroxetine—Nausea—Gemcitabine—kidney cancer	4.17e-05	0.00014	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Capecitabine—kidney cancer	4.16e-05	0.00014	CcSEcCtD
Paroxetine—Fatigue—Capecitabine—kidney cancer	4.15e-05	0.00014	CcSEcCtD
Paroxetine—Pruritus—Paclitaxel—kidney cancer	4.15e-05	0.00014	CcSEcCtD
Paroxetine—Erythema multiforme—Doxorubicin—kidney cancer	4.13e-05	0.000139	CcSEcCtD
Paroxetine—Constipation—Capecitabine—kidney cancer	4.12e-05	0.000139	CcSEcCtD
Paroxetine—Pain—Capecitabine—kidney cancer	4.12e-05	0.000139	CcSEcCtD
Paroxetine—Eye disorder—Doxorubicin—kidney cancer	4.09e-05	0.000137	CcSEcCtD
Paroxetine—Tinnitus—Doxorubicin—kidney cancer	4.08e-05	0.000137	CcSEcCtD
Paroxetine—Cardiac disorder—Doxorubicin—kidney cancer	4.06e-05	0.000136	CcSEcCtD
Paroxetine—Flushing—Doxorubicin—kidney cancer	4.06e-05	0.000136	CcSEcCtD
Paroxetine—Diarrhoea—Paclitaxel—kidney cancer	4.02e-05	0.000135	CcSEcCtD
Paroxetine—Feeling abnormal—Capecitabine—kidney cancer	3.97e-05	0.000133	CcSEcCtD
Paroxetine—Angiopathy—Doxorubicin—kidney cancer	3.97e-05	0.000133	CcSEcCtD
Paroxetine—Immune system disorder—Doxorubicin—kidney cancer	3.95e-05	0.000133	CcSEcCtD
Paroxetine—Gastrointestinal pain—Capecitabine—kidney cancer	3.94e-05	0.000132	CcSEcCtD
Paroxetine—Mediastinal disorder—Doxorubicin—kidney cancer	3.94e-05	0.000132	CcSEcCtD
Paroxetine—Chills—Doxorubicin—kidney cancer	3.92e-05	0.000132	CcSEcCtD
Paroxetine—Arrhythmia—Doxorubicin—kidney cancer	3.91e-05	0.000131	CcSEcCtD
Paroxetine—Dizziness—Paclitaxel—kidney cancer	3.88e-05	0.000131	CcSEcCtD
Paroxetine—Alopecia—Doxorubicin—kidney cancer	3.86e-05	0.00013	CcSEcCtD
Paroxetine—Mental disorder—Doxorubicin—kidney cancer	3.83e-05	0.000129	CcSEcCtD
Paroxetine—Urticaria—Capecitabine—kidney cancer	3.83e-05	0.000129	CcSEcCtD
Paroxetine—Body temperature increased—Capecitabine—kidney cancer	3.81e-05	0.000128	CcSEcCtD
Paroxetine—Abdominal pain—Capecitabine—kidney cancer	3.81e-05	0.000128	CcSEcCtD
Paroxetine—Erythema—Doxorubicin—kidney cancer	3.81e-05	0.000128	CcSEcCtD
Paroxetine—Malnutrition—Doxorubicin—kidney cancer	3.81e-05	0.000128	CcSEcCtD
Paroxetine—Flatulence—Doxorubicin—kidney cancer	3.75e-05	0.000126	CcSEcCtD
Paroxetine—Tension—Doxorubicin—kidney cancer	3.73e-05	0.000126	CcSEcCtD
Paroxetine—Vomiting—Paclitaxel—kidney cancer	3.73e-05	0.000125	CcSEcCtD
Paroxetine—Dysgeusia—Doxorubicin—kidney cancer	3.73e-05	0.000125	CcSEcCtD
Paroxetine—Rash—Paclitaxel—kidney cancer	3.7e-05	0.000124	CcSEcCtD
Paroxetine—Dermatitis—Paclitaxel—kidney cancer	3.7e-05	0.000124	CcSEcCtD
Paroxetine—Nervousness—Doxorubicin—kidney cancer	3.7e-05	0.000124	CcSEcCtD
Paroxetine—Back pain—Doxorubicin—kidney cancer	3.68e-05	0.000124	CcSEcCtD
Paroxetine—Headache—Paclitaxel—kidney cancer	3.68e-05	0.000124	CcSEcCtD
Paroxetine—Muscle spasms—Doxorubicin—kidney cancer	3.66e-05	0.000123	CcSEcCtD
Paroxetine—Vision blurred—Doxorubicin—kidney cancer	3.59e-05	0.000121	CcSEcCtD
Paroxetine—Hypersensitivity—Capecitabine—kidney cancer	3.55e-05	0.000119	CcSEcCtD
Paroxetine—Ill-defined disorder—Doxorubicin—kidney cancer	3.53e-05	0.000119	CcSEcCtD
Paroxetine—Anaemia—Doxorubicin—kidney cancer	3.52e-05	0.000118	CcSEcCtD
Paroxetine—Agitation—Doxorubicin—kidney cancer	3.5e-05	0.000118	CcSEcCtD
Paroxetine—Nausea—Paclitaxel—kidney cancer	3.49e-05	0.000117	CcSEcCtD
Paroxetine—Asthenia—Capecitabine—kidney cancer	3.46e-05	0.000116	CcSEcCtD
Paroxetine—Malaise—Doxorubicin—kidney cancer	3.43e-05	0.000115	CcSEcCtD
Paroxetine—Vertigo—Doxorubicin—kidney cancer	3.42e-05	0.000115	CcSEcCtD
Paroxetine—Syncope—Doxorubicin—kidney cancer	3.41e-05	0.000115	CcSEcCtD
Paroxetine—Pruritus—Capecitabine—kidney cancer	3.41e-05	0.000115	CcSEcCtD
Paroxetine—Leukopenia—Doxorubicin—kidney cancer	3.41e-05	0.000115	CcSEcCtD
Paroxetine—Palpitations—Doxorubicin—kidney cancer	3.36e-05	0.000113	CcSEcCtD
Paroxetine—Loss of consciousness—Doxorubicin—kidney cancer	3.35e-05	0.000112	CcSEcCtD
Paroxetine—Cough—Doxorubicin—kidney cancer	3.32e-05	0.000112	CcSEcCtD
Paroxetine—Convulsion—Doxorubicin—kidney cancer	3.3e-05	0.000111	CcSEcCtD
Paroxetine—Diarrhoea—Capecitabine—kidney cancer	3.3e-05	0.000111	CcSEcCtD
Paroxetine—Hypertension—Doxorubicin—kidney cancer	3.29e-05	0.00011	CcSEcCtD
Paroxetine—Arthralgia—Doxorubicin—kidney cancer	3.24e-05	0.000109	CcSEcCtD
Paroxetine—Myalgia—Doxorubicin—kidney cancer	3.24e-05	0.000109	CcSEcCtD
Paroxetine—Chest pain—Doxorubicin—kidney cancer	3.24e-05	0.000109	CcSEcCtD
Paroxetine—Anxiety—Doxorubicin—kidney cancer	3.23e-05	0.000109	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	3.22e-05	0.000108	CcSEcCtD
Paroxetine—Discomfort—Doxorubicin—kidney cancer	3.2e-05	0.000108	CcSEcCtD
Paroxetine—Dizziness—Capecitabine—kidney cancer	3.19e-05	0.000107	CcSEcCtD
Paroxetine—Dry mouth—Doxorubicin—kidney cancer	3.17e-05	0.000107	CcSEcCtD
Paroxetine—Confusional state—Doxorubicin—kidney cancer	3.13e-05	0.000105	CcSEcCtD
Paroxetine—Anaphylactic shock—Doxorubicin—kidney cancer	3.11e-05	0.000104	CcSEcCtD
Paroxetine—Oedema—Doxorubicin—kidney cancer	3.11e-05	0.000104	CcSEcCtD
Paroxetine—Infection—Doxorubicin—kidney cancer	3.09e-05	0.000104	CcSEcCtD
Paroxetine—Vomiting—Capecitabine—kidney cancer	3.06e-05	0.000103	CcSEcCtD
Paroxetine—Shock—Doxorubicin—kidney cancer	3.06e-05	0.000103	CcSEcCtD
Paroxetine—Nervous system disorder—Doxorubicin—kidney cancer	3.05e-05	0.000102	CcSEcCtD
Paroxetine—Thrombocytopenia—Doxorubicin—kidney cancer	3.04e-05	0.000102	CcSEcCtD
Paroxetine—Rash—Capecitabine—kidney cancer	3.04e-05	0.000102	CcSEcCtD
Paroxetine—Dermatitis—Capecitabine—kidney cancer	3.04e-05	0.000102	CcSEcCtD
Paroxetine—Tachycardia—Doxorubicin—kidney cancer	3.03e-05	0.000102	CcSEcCtD
Paroxetine—Headache—Capecitabine—kidney cancer	3.02e-05	0.000101	CcSEcCtD
Paroxetine—Skin disorder—Doxorubicin—kidney cancer	3.02e-05	0.000101	CcSEcCtD
Paroxetine—Hyperhidrosis—Doxorubicin—kidney cancer	3e-05	0.000101	CcSEcCtD
Paroxetine—Hypotension—Doxorubicin—kidney cancer	2.9e-05	9.76e-05	CcSEcCtD
Paroxetine—Nausea—Capecitabine—kidney cancer	2.86e-05	9.62e-05	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.83e-05	9.51e-05	CcSEcCtD
Paroxetine—Insomnia—Doxorubicin—kidney cancer	2.81e-05	9.44e-05	CcSEcCtD
Paroxetine—Paraesthesia—Doxorubicin—kidney cancer	2.79e-05	9.38e-05	CcSEcCtD
Paroxetine—Dyspnoea—Doxorubicin—kidney cancer	2.77e-05	9.31e-05	CcSEcCtD
Paroxetine—Somnolence—Doxorubicin—kidney cancer	2.76e-05	9.28e-05	CcSEcCtD
Paroxetine—Dyspepsia—Doxorubicin—kidney cancer	2.73e-05	9.19e-05	CcSEcCtD
Paroxetine—Decreased appetite—Doxorubicin—kidney cancer	2.7e-05	9.08e-05	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Doxorubicin—kidney cancer	2.68e-05	9.01e-05	CcSEcCtD
Paroxetine—Fatigue—Doxorubicin—kidney cancer	2.68e-05	9e-05	CcSEcCtD
Paroxetine—Constipation—Doxorubicin—kidney cancer	2.66e-05	8.93e-05	CcSEcCtD
Paroxetine—Pain—Doxorubicin—kidney cancer	2.66e-05	8.93e-05	CcSEcCtD
Paroxetine—Feeling abnormal—Doxorubicin—kidney cancer	2.56e-05	8.6e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Doxorubicin—kidney cancer	2.54e-05	8.54e-05	CcSEcCtD
Paroxetine—Urticaria—Doxorubicin—kidney cancer	2.47e-05	8.29e-05	CcSEcCtD
Paroxetine—Abdominal pain—Doxorubicin—kidney cancer	2.46e-05	8.25e-05	CcSEcCtD
Paroxetine—Body temperature increased—Doxorubicin—kidney cancer	2.46e-05	8.25e-05	CcSEcCtD
Paroxetine—Hypersensitivity—Doxorubicin—kidney cancer	2.29e-05	7.69e-05	CcSEcCtD
Paroxetine—Asthenia—Doxorubicin—kidney cancer	2.23e-05	7.49e-05	CcSEcCtD
Paroxetine—Pruritus—Doxorubicin—kidney cancer	2.2e-05	7.39e-05	CcSEcCtD
Paroxetine—Diarrhoea—Doxorubicin—kidney cancer	2.13e-05	7.14e-05	CcSEcCtD
Paroxetine—Dizziness—Doxorubicin—kidney cancer	2.05e-05	6.9e-05	CcSEcCtD
Paroxetine—Vomiting—Doxorubicin—kidney cancer	1.97e-05	6.64e-05	CcSEcCtD
Paroxetine—Rash—Doxorubicin—kidney cancer	1.96e-05	6.58e-05	CcSEcCtD
Paroxetine—Dermatitis—Doxorubicin—kidney cancer	1.96e-05	6.58e-05	CcSEcCtD
Paroxetine—Headache—Doxorubicin—kidney cancer	1.95e-05	6.54e-05	CcSEcCtD
Paroxetine—Nausea—Doxorubicin—kidney cancer	1.85e-05	6.2e-05	CcSEcCtD
Paroxetine—CHRM1—Signaling Pathways—IGF2—kidney cancer	7.33e-06	0.000147	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ABCB1—kidney cancer	7.32e-06	0.000147	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF2—kidney cancer	7.31e-06	0.000147	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—MAPK3—kidney cancer	7.31e-06	0.000147	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KIT—kidney cancer	7.3e-06	0.000147	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—APC—kidney cancer	7.3e-06	0.000147	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN2B—kidney cancer	7.3e-06	0.000147	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN2B—kidney cancer	7.28e-06	0.000146	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SCARB1—kidney cancer	7.27e-06	0.000146	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS1—kidney cancer	7.26e-06	0.000146	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—POMC—kidney cancer	7.26e-06	0.000146	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF2—kidney cancer	7.24e-06	0.000145	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN2B—kidney cancer	7.21e-06	0.000145	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS1—kidney cancer	7.2e-06	0.000145	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—BRAF—kidney cancer	7.17e-06	0.000144	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—BCHE—kidney cancer	7.17e-06	0.000144	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1R—kidney cancer	7.13e-06	0.000143	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PSMD7—kidney cancer	7.12e-06	0.000143	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GSTM1—kidney cancer	7.1e-06	0.000143	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1R—kidney cancer	7.09e-06	0.000142	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SLC5A5—kidney cancer	7.08e-06	0.000142	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1R—kidney cancer	7.07e-06	0.000142	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PSMD7—kidney cancer	7.06e-06	0.000142	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1R—kidney cancer	7e-06	0.000141	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—MAPK3—kidney cancer	7e-06	0.00014	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—POMC—kidney cancer	6.95e-06	0.00014	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—MAPK1—kidney cancer	6.95e-06	0.00014	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—RAF1—kidney cancer	6.87e-06	0.000138	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—BRAF—kidney cancer	6.87e-06	0.000138	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SLC2A1—kidney cancer	6.84e-06	0.000137	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—RAF1—kidney cancer	6.83e-06	0.000137	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—RAF1—kidney cancer	6.81e-06	0.000137	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—IL2—kidney cancer	6.78e-06	0.000136	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—BCHE—kidney cancer	6.75e-06	0.000136	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—IL2—kidney cancer	6.75e-06	0.000135	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—RAF1—kidney cancer	6.75e-06	0.000135	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYP1A1—kidney cancer	6.73e-06	0.000135	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—IL2—kidney cancer	6.73e-06	0.000135	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—BCHE—kidney cancer	6.69e-06	0.000134	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SLC5A5—kidney cancer	6.67e-06	0.000134	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—IL2—kidney cancer	6.66e-06	0.000134	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—MAPK1—kidney cancer	6.66e-06	0.000134	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—PIK3CA—kidney cancer	6.64e-06	0.000133	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	6.64e-06	0.000133	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SLC5A5—kidney cancer	6.61e-06	0.000133	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—KRAS—kidney cancer	6.57e-06	0.000132	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTP1—kidney cancer	6.54e-06	0.000131	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	6.52e-06	0.000131	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SLC2A1—kidney cancer	6.44e-06	0.000129	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SLC2A1—kidney cancer	6.39e-06	0.000128	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—PIK3CA—kidney cancer	6.36e-06	0.000128	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—KRAS—kidney cancer	6.29e-06	0.000126	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	6.2e-06	0.000124	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ABCB1—kidney cancer	6.2e-06	0.000124	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL2—kidney cancer	6.16e-06	0.000124	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL2—kidney cancer	6.13e-06	0.000123	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL2—kidney cancer	6.11e-06	0.000123	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL2—kidney cancer	6.05e-06	0.000121	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—PIK3CA—kidney cancer	6.03e-06	0.000121	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTM1—kidney cancer	6.01e-06	0.000121	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—RAF1—kidney cancer	5.99e-06	0.00012	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—RELA—kidney cancer	5.96e-06	0.00012	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ERBB2—kidney cancer	5.92e-06	0.000119	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HIF1A—kidney cancer	5.87e-06	0.000118	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TSC2—kidney cancer	5.86e-06	0.000118	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MTOR—kidney cancer	5.84e-06	0.000117	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HIF1A—kidney cancer	5.84e-06	0.000117	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—POMC—kidney cancer	5.84e-06	0.000117	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TSC2—kidney cancer	5.82e-06	0.000117	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HIF1A—kidney cancer	5.82e-06	0.000117	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TSC2—kidney cancer	5.81e-06	0.000117	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—PIK3CA—kidney cancer	5.78e-06	0.000116	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HIF1A—kidney cancer	5.76e-06	0.000116	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TSC2—kidney cancer	5.75e-06	0.000115	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RAF1—kidney cancer	5.73e-06	0.000115	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RELA—kidney cancer	5.71e-06	0.000115	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTP1—kidney cancer	5.7e-06	0.000114	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP1A1—kidney cancer	5.7e-06	0.000114	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ERBB2—kidney cancer	5.67e-06	0.000114	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KDR—kidney cancer	5.61e-06	0.000113	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MTOR—kidney cancer	5.6e-06	0.000112	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KDR—kidney cancer	5.58e-06	0.000112	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KDR—kidney cancer	5.57e-06	0.000112	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KDR—kidney cancer	5.51e-06	0.000111	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CDKN1B—kidney cancer	5.49e-06	0.00011	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.4e-06	0.000108	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTP1—kidney cancer	5.37e-06	0.000108	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL2—kidney cancer	5.37e-06	0.000108	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTP1—kidney cancer	5.33e-06	0.000107	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CDKN1B—kidney cancer	5.25e-06	0.000105	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTM1—kidney cancer	5.24e-06	0.000105	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCND1—kidney cancer	5.23e-06	0.000105	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—JUN—kidney cancer	5.22e-06	0.000105	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CTNNB1—kidney cancer	5.18e-06	0.000104	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APC—kidney cancer	5.17e-06	0.000104	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KIT—kidney cancer	5.17e-06	0.000104	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APC—kidney cancer	5.14e-06	0.000103	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KIT—kidney cancer	5.14e-06	0.000103	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL2—kidney cancer	5.14e-06	0.000103	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KIT—kidney cancer	5.13e-06	0.000103	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APC—kidney cancer	5.13e-06	0.000103	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ABCB1—kidney cancer	5.09e-06	0.000102	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KIT—kidney cancer	5.08e-06	0.000102	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APC—kidney cancer	5.08e-06	0.000102	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PTEN—kidney cancer	5.05e-06	0.000101	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ABCB1—kidney cancer	5.04e-06	0.000101	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—POMC—kidney cancer	5.02e-06	0.000101	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCND1—kidney cancer	5.01e-06	0.000101	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—JUN—kidney cancer	5e-06	0.0001	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP1A1—kidney cancer	4.97e-06	9.97e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CTNNB1—kidney cancer	4.96e-06	9.96e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—MAPK3—kidney cancer	4.95e-06	9.94e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTM1—kidney cancer	4.94e-06	9.91e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—MAPK3—kidney cancer	4.93e-06	9.89e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—POMC—kidney cancer	4.92e-06	9.88e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—MAPK3—kidney cancer	4.91e-06	9.86e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—POMC—kidney cancer	4.9e-06	9.83e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTM1—kidney cancer	4.89e-06	9.82e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—POMC—kidney cancer	4.88e-06	9.8e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—MAPK3—kidney cancer	4.86e-06	9.76e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—BRAF—kidney cancer	4.86e-06	9.76e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTEN—kidney cancer	4.84e-06	9.71e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—BRAF—kidney cancer	4.83e-06	9.7e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—POMC—kidney cancer	4.83e-06	9.7e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—BRAF—kidney cancer	4.82e-06	9.67e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—BRAF—kidney cancer	4.77e-06	9.58e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—MAPK1—kidney cancer	4.71e-06	9.46e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—MAPK1—kidney cancer	4.69e-06	9.41e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.68e-06	9.4e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP1A1—kidney cancer	4.68e-06	9.39e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—MAPK1—kidney cancer	4.67e-06	9.38e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—kidney cancer	4.66e-06	9.34e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP1A1—kidney cancer	4.64e-06	9.31e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—MAPK1—kidney cancer	4.63e-06	9.29e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—kidney cancer	4.56e-06	9.16e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—PIK3CA—kidney cancer	4.5e-06	9.04e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—PIK3CA—kidney cancer	4.48e-06	8.99e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—PIK3CA—kidney cancer	4.46e-06	8.96e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—KRAS—kidney cancer	4.45e-06	8.93e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—KRAS—kidney cancer	4.43e-06	8.89e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—PIK3CA—kidney cancer	4.42e-06	8.87e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—KRAS—kidney cancer	4.41e-06	8.86e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—KRAS—kidney cancer	4.37e-06	8.77e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—kidney cancer	4.37e-06	8.77e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK3—kidney cancer	4.32e-06	8.66e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—POMC—kidney cancer	4.25e-06	8.53e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MYC—kidney cancer	4.2e-06	8.42e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK3—kidney cancer	4.13e-06	8.3e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK1—kidney cancer	4.11e-06	8.24e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	4.09e-06	8.21e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PIK3CA—kidney cancer	4.07e-06	8.16e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTEN—kidney cancer	4.06e-06	8.15e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RAF1—kidney cancer	4.06e-06	8.15e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PIK3CA—kidney cancer	4.05e-06	8.14e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RELA—kidney cancer	4.04e-06	8.11e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RAF1—kidney cancer	4.04e-06	8.1e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RAF1—kidney cancer	4.02e-06	8.08e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MYC—kidney cancer	4.02e-06	8.07e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RELA—kidney cancer	4.02e-06	8.07e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ERBB2—kidney cancer	4.02e-06	8.06e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PIK3CA—kidney cancer	4.01e-06	8.06e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RELA—kidney cancer	4.01e-06	8.04e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—kidney cancer	4e-06	8.04e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ERBB2—kidney cancer	3.99e-06	8.02e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RAF1—kidney cancer	3.98e-06	8e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ERBB2—kidney cancer	3.98e-06	7.99e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RELA—kidney cancer	3.97e-06	7.96e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MTOR—kidney cancer	3.96e-06	7.95e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ERBB2—kidney cancer	3.94e-06	7.91e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MTOR—kidney cancer	3.94e-06	7.91e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK1—kidney cancer	3.93e-06	7.89e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MTOR—kidney cancer	3.93e-06	7.89e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MTOR—kidney cancer	3.89e-06	7.81e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KRAS—kidney cancer	3.88e-06	7.78e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.81e-06	7.65e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	3.72e-06	7.46e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KRAS—kidney cancer	3.71e-06	7.45e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—POMC—kidney cancer	3.7e-06	7.43e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN1B—kidney cancer	3.7e-06	7.42e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN1B—kidney cancer	3.69e-06	7.4e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN1B—kidney cancer	3.65e-06	7.33e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL2—kidney cancer	3.64e-06	7.3e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL2—kidney cancer	3.62e-06	7.26e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL2—kidney cancer	3.61e-06	7.24e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL2—kidney cancer	3.57e-06	7.17e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PIK3CA—kidney cancer	3.56e-06	7.15e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCND1—kidney cancer	3.55e-06	7.12e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—JUN—kidney cancer	3.54e-06	7.11e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCND1—kidney cancer	3.53e-06	7.08e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—JUN—kidney cancer	3.52e-06	7.07e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCND1—kidney cancer	3.52e-06	7.06e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	3.51e-06	7.05e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—JUN—kidney cancer	3.51e-06	7.04e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CTNNB1—kidney cancer	3.49e-06	7.01e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTEN—kidney cancer	3.49e-06	7.01e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—POMC—kidney cancer	3.49e-06	7e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCND1—kidney cancer	3.48e-06	6.99e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CTNNB1—kidney cancer	3.48e-06	6.99e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—JUN—kidney cancer	3.48e-06	6.98e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—POMC—kidney cancer	3.46e-06	6.94e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CTNNB1—kidney cancer	3.45e-06	6.92e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—kidney cancer	3.45e-06	6.92e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTEN—kidney cancer	3.42e-06	6.87e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PIK3CA—kidney cancer	3.41e-06	6.85e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTEN—kidney cancer	3.41e-06	6.84e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTEN—kidney cancer	3.39e-06	6.81e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—kidney cancer	3.39e-06	6.81e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTEN—kidney cancer	3.36e-06	6.75e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—kidney cancer	3.3e-06	6.63e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—kidney cancer	3.09e-06	6.21e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—kidney cancer	3.08e-06	6.17e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—kidney cancer	3.07e-06	6.15e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—kidney cancer	3.04e-06	6.09e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTEN—kidney cancer	2.96e-06	5.93e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—kidney cancer	2.95e-06	5.93e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK3—kidney cancer	2.93e-06	5.87e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK3—kidney cancer	2.91e-06	5.84e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK3—kidney cancer	2.9e-06	5.82e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK3—kidney cancer	2.87e-06	5.77e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CA—kidney cancer	2.86e-06	5.75e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MYC—kidney cancer	2.85e-06	5.71e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MYC—kidney cancer	2.83e-06	5.68e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MYC—kidney cancer	2.82e-06	5.66e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MYC—kidney cancer	2.79e-06	5.61e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK1—kidney cancer	2.78e-06	5.59e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—kidney cancer	2.78e-06	5.59e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK1—kidney cancer	2.77e-06	5.56e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK1—kidney cancer	2.76e-06	5.54e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—kidney cancer	2.76e-06	5.54e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK1—kidney cancer	2.73e-06	5.49e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KRAS—kidney cancer	2.63e-06	5.28e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KRAS—kidney cancer	2.62e-06	5.25e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KRAS—kidney cancer	2.61e-06	5.23e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KRAS—kidney cancer	2.58e-06	5.18e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTEN—kidney cancer	2.58e-06	5.17e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CA—kidney cancer	2.46e-06	4.95e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTEN—kidney cancer	2.43e-06	4.87e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	2.42e-06	4.85e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTEN—kidney cancer	2.41e-06	4.83e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CA—kidney cancer	2.4e-06	4.82e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CA—kidney cancer	2.39e-06	4.81e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CA—kidney cancer	2.37e-06	4.76e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—kidney cancer	2.34e-06	4.69e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—kidney cancer	2.32e-06	4.67e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—kidney cancer	2.32e-06	4.65e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—kidney cancer	2.29e-06	4.61e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CA—kidney cancer	2.09e-06	4.19e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CA—kidney cancer	1.82e-06	3.65e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.71e-06	3.44e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.7e-06	3.41e-05	CbGpPWpGaD
